Other

Hong Kong IPO disclosure precedents · 5 companies, 5 items

2026-08-20Application Proof
Junlebao Dairy Group Co., Ltd.君乐宝乳业集团股份有限公司

As of June 30, 2026, the aggregate revenue generated from such distributors amounted to RMB201.7 million, RMB266.1 million, RMB306.9 million and RMB153.3 million in 2023, 2024, 2025 and for the six months ended June 30, 2026, representing 1.1%, 1.3%, 1.5% and 1.4% of our total revenue for the same periods, respectively

Business · p. 145

In aggregate, the revenue generated from the abovementioned distributors amounted to RMB230.3 million, RMB380.3 million, RMB426.9 million and RMB205.9 million in 2023, 2024, 2025 and for the six months ended June 30, 2026, representing 1.3%, 1.9%, 2.1% and 1.9% of our total revenue for the same periods, respectively.

Business · p. 146

The abovementioned distributors were engaged following the same standards as other distributors, becoming our distributors based on their qualifications and capabilities, and the salient terms of their distribution agreements are consistent with those of other distributors' distribution agreements.

Business · p. 146
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-03-31Application Proof
Changzhou Microintelligence Co., Ltd常州微亿智造科技股份有限公司

Shanghai Jiebote is a limited partnership whose general partner is ultimately controlled by Mr. He Yan, a non-executive Director of the Company.

Financial Information · p. 230

The consideration was determined through arm's length negotiations and was consistent with the valuation and commercial terms offered to independent third-party sellers in the same transaction batch.

Financial Information · p. 230

Our Directors are of the view that these related party transactions were conducted on normal commercial terms and an arm's length basis.

Financial Information · p. 230
The company's explanation, the adviser's view and the page in the filing: see Matters
2025-11-14Prospectus
Chuangxin Industries Holdings Limited创新实业集团有限公司02788.HK

Our Company co-invested with our Controlling Shareholders’ close associates, namely Innovation Group and Innovation New Material, in the Saudi Project.

Summary · p. 4

Our Directors believe that the co-investment into the Saudi Project is beneficial to the Company and our Shareholders as a whole and does not indicate any undue reliance on, or direct competition with, our Controlling Shareholders’ close associates.

Summary · p. 4
The company's explanation, the adviser's view and the page in the filing: see Matters
2024-08-26Prospectus
GUANGDONG SYNTRUST GK TESTING AND CERTIFICATION TECH SERVICE CENTER CO., LTD.广东集信国控检测认证技术服务中心股份有限公司08629.HK

We provided testing services to our Controlling Shareholder. In FY2021, FY2022, FY2023 and 6M2024, the transaction amounts were RMB200, nil, RMB85,000 and RMB43,000.

Financial Information · p. 344

Two loans with principal amounts of RMB3.75 million and RMB4.1 million were granted to Xinyi Xinye in January 2023 and March 2023, respectively.

Financial Information · p. 344

In December 2023, the loans and interest were fully repaid.

Financial Information · p. 344
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-08-24Prospectus
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.宜明昂科生物医药技术(上海)股份有限公司01541.HK

we issued restricted shares to Dr. Ding.

Financial Information · p. 399

we recognized RMB5.6 million, RMB6.0 million, and RMB0.7 million in 2021, 2022 and the four months ended April 30, 2023, respectively, for the expenses of the share-based payment for her compensation according to the accounting standard.

Financial Information · p. 399

It is the view of our Directors that our related party transactions during the Track Record Period (i) were conducted in the ordinary and usual course of business and on normal commercial terms between the relevant parties, and (ii) do not distort our Track Record Period results or make our historical results not reflective of future performance.

Financial Information · p. 400
The company's explanation, the adviser's view and the page in the filing: see Matters

Tell us